Organisation paid for research Program year 2025 Source: CMS Open Payments

Optiskin Medical

Neither a doctor nor a teaching hospital

Research payments

$538,709

13 payments

Through program year 2025, Optiskin Medical is reported as receiving $538,709 in research payments, across 13 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$98,145	3
2024	Research	$132,017	5
2023	Research	$9,522	3
2022	Research	$201,018	1
2021	Research	$98,008	1

Breakdown

Who paid Research payments · program years 2021–2025

Amgen Inc. $439,113 8 payments
Takeda Pharmaceuticals U.S.A., Inc. $98,145 3 payments
Pfizer Inc. $1,452 2 payments

Studies the money was for Research payments · program years 2021–2025

Monitoring nail changes in patients with psoriatic disease treated with etanercept using non-invasive Optical Coherence Tomography $299,025 2 payments
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $98,145 3 payments
HORIZON P3 AD Monotherapy Induction $67,625 2 payments
ASCEND P3 AD Extension $56,323 2 payments
P3 AD Monotherapy Induction $8,070 1 payment
Ph3 Otezla in Peds mild/mod PsO PMR $8,069 1 payment
A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $1,452 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.